These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 39256488)

  • 1. Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial.
    Li K; Zhong W; Fan J; Wang S; Yu D; Xu T; Lyu J; Wu S; Qin T; Wu Z; Xu L; Wu K; Liu Z; Hu Z; Li F; Wang J; Wang Q; Min J; Zhang Z; Yu L; Ding S; Huang L; Zhao T; Huang J; Lin T
    Nat Cancer; 2024 Oct; 5(10):1465-1478. PubMed ID: 39256488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study.
    Luo C; Luo S; Wusimanjiang W; Wang Z; Liu P; Wang B; Yuan D; Lin H; Xu A; Deng N; Wu K; Zhu X; Xu P; Chen J; Huang B
    Clin Transl Oncol; 2024 Jul; 26(7):1759-1767. PubMed ID: 38472556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
    Rose TL; Harrison MR; Deal AM; Ramalingam S; Whang YE; Brower B; Dunn M; Osterman CK; Heiling HM; Bjurlin MA; Smith AB; Nielsen ME; Tan HJ; Wallen E; Woods ME; George D; Zhang T; Drier A; Kim WY; Milowsky MI
    J Clin Oncol; 2021 Oct; 39(28):3140-3148. PubMed ID: 34428076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
    Meleis L; Moore R; Inman BA; Harrison MR
    J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
    Funt SA; Lattanzi M; Whiting K; Al-Ahmadie H; Quinlan C; Teo MY; Lee CH; Aggen D; Zimmerman D; McHugh D; Apollo A; Durdin TD; Truong H; Kamradt J; Khalil M; Lash B; Ostrovnaya I; McCoy AS; Hettich G; Regazzi A; Jihad M; Ratna N; Boswell A; Francese K; Yang Y; Folefac E; Herr HW; Donat SM; Pietzak E; Cha EK; Donahue TF; Goh AC; Huang WC; Bajorin DF; Iyer G; Bochner BH; Balar AV; Mortazavi A; Rosenberg JE
    J Clin Oncol; 2022 Apr; 40(12):1312-1322. PubMed ID: 35089812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
    Grivas P; Koshkin VS; Chu X; Cole S; Jain RK; Dreicer R; Cetnar JP; Sundi D; Gartrell BA; Galsky MD; Woo B; Li-Ning-Tapia E; Hahn NM; Carducci MA
    Eur Urol Oncol; 2024 Aug; 7(4):914-922. PubMed ID: 38155060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
    Martinez Chanza N; Soukane L; Barthelemy P; Carnot A; Gil T; Casert V; Vanhaudenarde V; Sautois B; Staudacher L; Van den Brande J; Culine S; Seront E; Gizzi M; Albisinni S; Tricard T; Fantoni JC; Paesmans M; Caparica R; Roumeguere T; Awada A
    BMC Cancer; 2021 Dec; 21(1):1292. PubMed ID: 34856936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study.
    Han S; Ji Z; Jiang J; Fan X; Ma Q; Hu L; Zhang W; Ping H; Wang J; Xu W; Shi B; Wang W; Wang H; Wang H; Chen S; Hu H; Guo J; Zhang S; Jiang S; Zhou Q; Xing N
    Cancer Med; 2023 Jun; 12(11):12106-12117. PubMed ID: 37021811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
    Narayan V; Mamtani R; Keefe S; Guzzo T; Malkowicz SB; Vaughn DJ
    Cancer Res Treat; 2016 Jul; 48(3):1084-91. PubMed ID: 26639198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
    Iyer G; Balar AV; Milowsky MI; Bochner BH; Dalbagni G; Donat SM; Herr HW; Huang WC; Taneja SS; Woods M; Ostrovnaya I; Al-Ahmadie H; Arcila ME; Riches JC; Meier A; Bourque C; Shady M; Won H; Rose TL; Kim WY; Kania BE; Boyd ME; Cipolla CK; Regazzi AM; Delbeau D; McCoy AS; Vargas HA; Berger MF; Solit DB; Rosenberg JE; Bajorin DF
    J Clin Oncol; 2018 Jul; 36(19):1949-1956. PubMed ID: 29742009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
    Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
    Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
    Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
    Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
    J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.
    Daneshmand S; Brummelhuis ISG; Pohar KS; Steinberg GD; Aron M; Cutie CJ; Keegan KA; Maffeo JC; Reynolds DL; Raybold B; Chau A; Witjes JA
    Urol Oncol; 2022 Jul; 40(7):344.e1-344.e9. PubMed ID: 35431132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
    Beckabir W; Zhou M; Lee JS; Vensko SP; Woodcock MG; Wang HH; Wobker SE; Atassi G; Wilkinson AD; Fowler K; Flick LM; Damrauer JS; Harrison MR; McKinnon KP; Rose TL; Milowsky MI; Serody JS; Kim WY; Vincent BG
    Nat Commun; 2024 May; 15(1):4448. PubMed ID: 38789460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen.
    Eule CJ; Warren A; Molina Kuna E; Callihan EB; Kim SP; Flaig TW
    Urology; 2024 Jun; 188():118-124. PubMed ID: 38685388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
    Afferi L; Spahn M; Hayoz S; Strebel RT; Rothschild SI; Seifert H; Özdemir BC; Kiss B; Maletzki P; Engeler D; Wirth G; Hadaschik B; Lucca I; John H; Sauer A; Müntener M; Bubendorf L; Schneider M; Musilova J; Petrausch U; Cathomas R;
    BJU Int; 2024 Sep; 134(3):388-397. PubMed ID: 38456541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Zargar H; Espiritu PN; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Vasdev N; Yu EY; Youssef D; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Garcia JA; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
    Eur Urol; 2015 Feb; 67(2):241-9. PubMed ID: 25257030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies.
    Cho SW; Lim SH; Kwon GY; Kim CK; Park W; Pyo H; Chung JH; Song W; Sung HH; Jeong BC; Park SH
    Cancer Res Treat; 2024 Jul; 56(3):893-897. PubMed ID: 38374699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.